-
Something wrong with this record ?
Biomarkers in critically ill patients with systemic inflammatory response syndrome or sepsis supplemented with high-dose selenium
H. Brodska, J. Valenta, K. Malickova, P. Kohout, A. Kazda, T. Drabek,
Language English Country Germany
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- MeSH
- Biomarkers blood MeSH
- Glutathione Peroxidase blood MeSH
- Critical Illness MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Dietary Supplements MeSH
- Selenium blood pharmacology MeSH
- Aged MeSH
- Sepsis blood drug therapy mortality MeSH
- Systemic Inflammatory Response Syndrome blood drug therapy mortality MeSH
- Treatment Outcome MeSH
- Inflammation blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
OBJECTIVE: Low levels of selenium (Se) and glutathione peroxidase (GSHPx), a key selenoenzyme, were documented in systemic inflammatory response syndrome (SIRS) and sepsis, both associated with high mortality. Se supplementation had mixed effects on outcome. We hypothesized that Se supplementation could have a different impact on biomarkers and 28-day mortality in patients with SIRS vs. sepsis. METHODS: Adult patients with SIRS or sepsis were randomized to either high-dose (Se+, n = 75) or standard-dose (Se-, n = 75) Se supplementation. Plasma Se, whole blood GSHPx activity, C-reactive protein (CRP), procalcitonin (PCT), prealbumin, albumin and cholesterol levels were measured serially up to day 14. RESULTS: There was no difference in mortality between Se- (24/75) vs. Se+ group (19/75; p = 0.367) or between SIRS and septic patients (8/26 vs. 35/124; p = 0.794). There was a trend to reduced mortality in SIRS patients in the Se+ vs. Se- group (p = 0.084). Plasma Se levels increased in the Se+ group only in patients with sepsis but not in patients with SIRS. Plasma Se levels correlated with GSHPx. In SIRS/Se+ group, Se correlated only with GSHPx. In SIRS/Se- group, Se correlated with cholesterol but not with other biomarkers. In sepsis patients, Se levels correlated with cholesterol, GSHPx and prealbumin. Cholesterol levels were higher in survivors in the Se- group. CONCLUSIONS: Se levels correlated with GSHPx activity and other nutritional biomarkers with significant differences between SIRS and sepsis groups. High-dose Se supplementation did not affect mortality but a strong trend to decreased mortality in SIRS patients warrants further studies in this population.
Department of Anesthesiology University of Pittsburgh School of Medicine Pittsburgh PA United States
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010160
- 003
- CZ-PrNML
- 005
- 20160415104916.0
- 007
- ta
- 008
- 160408s2015 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jtemb.2015.02.005 $2 doi
- 024 7_
- $a 10.1016/j.jtemb.2015.02.005 $2 doi
- 035 __
- $a (PubMed)26004888
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Brodska, Helena $u Institute of Clinical Biochemistry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
- 245 10
- $a Biomarkers in critically ill patients with systemic inflammatory response syndrome or sepsis supplemented with high-dose selenium / $c H. Brodska, J. Valenta, K. Malickova, P. Kohout, A. Kazda, T. Drabek,
- 520 9_
- $a OBJECTIVE: Low levels of selenium (Se) and glutathione peroxidase (GSHPx), a key selenoenzyme, were documented in systemic inflammatory response syndrome (SIRS) and sepsis, both associated with high mortality. Se supplementation had mixed effects on outcome. We hypothesized that Se supplementation could have a different impact on biomarkers and 28-day mortality in patients with SIRS vs. sepsis. METHODS: Adult patients with SIRS or sepsis were randomized to either high-dose (Se+, n = 75) or standard-dose (Se-, n = 75) Se supplementation. Plasma Se, whole blood GSHPx activity, C-reactive protein (CRP), procalcitonin (PCT), prealbumin, albumin and cholesterol levels were measured serially up to day 14. RESULTS: There was no difference in mortality between Se- (24/75) vs. Se+ group (19/75; p = 0.367) or between SIRS and septic patients (8/26 vs. 35/124; p = 0.794). There was a trend to reduced mortality in SIRS patients in the Se+ vs. Se- group (p = 0.084). Plasma Se levels increased in the Se+ group only in patients with sepsis but not in patients with SIRS. Plasma Se levels correlated with GSHPx. In SIRS/Se+ group, Se correlated only with GSHPx. In SIRS/Se- group, Se correlated with cholesterol but not with other biomarkers. In sepsis patients, Se levels correlated with cholesterol, GSHPx and prealbumin. Cholesterol levels were higher in survivors in the Se- group. CONCLUSIONS: Se levels correlated with GSHPx activity and other nutritional biomarkers with significant differences between SIRS and sepsis groups. High-dose Se supplementation did not affect mortality but a strong trend to decreased mortality in SIRS patients warrants further studies in this population.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a kritický stav $7 D016638
- 650 _2
- $a potravní doplňky $7 D019587
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glutathionperoxidasa $x krev $7 D005979
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x krev $7 D007249
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a selen $x krev $x farmakologie $7 D012643
- 650 _2
- $a sepse $x krev $x farmakoterapie $x mortalita $7 D018805
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a syndrom systémové zánětlivé reakce $x krev $x farmakoterapie $x mortalita $7 D018746
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Valenta, Jiri $u Department of Anaesthesiology and Intensive Care, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Malickova, Karin $u Institute of Clinical Biochemistry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Kohout, Pavel $u Department of Internal Medicine, Nutrition and Dietetic Center, Thomayer University Hospital, Prague, Czech Republic.
- 700 1_
- $a Kazda, Antonin $u Institute of Clinical Biochemistry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Drabek, Tomas $u Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Electronic address: drabekt@anes.upmc.edu.
- 773 0_
- $w MED00003028 $t Journal of trace elements in medicine and biology organ of the Society for Minerals and Trace Elements (GMS) $x 1878-3252 $g Roč. 31, č. - (2015), s. 25-32
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26004888 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160415105001 $b ABA008
- 999 __
- $a ok $b bmc $g 1113589 $s 934528
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 31 $c - $d 25-32 $e 20150305 $i 1878-3252 $m Journal of trace elements in medicine and biology $n J Trace Elem Med Biol $x MED00003028
- LZP __
- $a Pubmed-20160408
